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ABSTRACT
Background and the purpose of the study: Various compounds from natural and synthetic 
origins containing the 1,3-diarylpropenone structure have been reported to produce a variety 
of biological activities like anti-microbial, anti-inflammatory, vascular muscle relaxant, etc. A 
systematic analysis of the structural features responsible for anti-inflammatory activity and a 
possible mode of their actions were proposed to be evaluated by synthesizing a set of compounds, 
screening them for anti-inflammatory activity and developing a QSAR model. 
Methods:  Two  types  of  1,3-diarylpropenone  derivatives  were  synthesized  employing  the 
Claisen-Schmidt condensation. These compounds were then screened for their in vivo anti-
inflammatory activity by the carrageenin induced rat paw edema method and also for in vitro 
cyclooxygenase-2 (COX-2) inhibition activity using a colorimetric kit for COX (ovine) inhibitor 
screening assay. These derivatives and their anti-inflammatory activity data were employed 
for QSAR analysis on Vlife MDS 3.5 software. The molecules were divided into training and 
test sets based on observed activity and QSAR models were generated for the training set and 
validated. The activity of the molecules of the test set was predicted according to the QSAR 
equation fit. Possible correlation between observed anti-inflammatory activity and in vitro 
cyclooxygenase-2 inhibition was also studied.
Results and conclusion: Insignificant difference between the observed and predicted biological 
activity revealed that the selected electronic, steric and lipophilic parameters have a significant 
correlation (r2 = 0.85) with anti-inflammatory activity of the selected class of compounds. On 
the basis of results it may be suggested that the 1,3-diaryl-2-propen-1-ones framework is an 
attractive template for structural optimization to achieve better potency of anti-inflammatory 
activity.  Similarly,  the  relatively  low  correlation  between  anti-inflammatory  activity  and 
cyclooxygenase-2 inhibition indicates that other modes of actions may also be responsible for 
the anti-inflammatory activity of the tested compounds.   
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INTRODUCTION 
It  is  well-documented  that  non-steroidal  anti-
inflammatory  drugs  (NSAIDs)  exert  their  effects 
through inhibition of prostaglandin (PG) synthesis, 
by blocking cyclooxygenase (COX) activity (1). Two 
isoforms of the COX enzyme, COX-1 and COX-2, 
with  their  functional  roles  in  the  maintenance  of 
normal homeostasis and induction of inflammation 
at inflammatory sites, respectively, were identified 
early  in  the  past  decade  (2,  3).  Extensive  efforts 
have been made to establish a correlation between 
structural  parameters  and  biological  activity  on 
diverse series of compounds using three-dimensional 
quantitative  structure-activity  relationship  (3D-
QSAR) studies (4).
The  presence  of  reactive  α,β-unsaturated  ketone 
group in propenones is reported to be responsible for 
their antimicrobial (5-10), vascular smooth relaxant 
(11),  nitric  oxide  scavenging  (12),  cholinesterase 
inhibitory (13), analgesic and anti-inflammatory (14-
16)  activities.  Progesterone  has  a  α,β-unsaturated 
ketone  group  and  is  reported  to  be  a  possible 
contributor to gingival inflammation by upregulation 
of COX-2 expression and subsequent prostaglandin 
formation  (17).  The  possibility  of  such  structural 
similarities contributing to affinity of interaction with 
common targets could always exist. Here we report 
the synthesis, anti-inflammatory activity screening 
and QSAR studies of substituted 1,3-diarylpropenone 
derivatives. All the compounds were screened for 
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Anti-inflammatory activity
In vivo anti-inflammatory activity 
The anti-inflammatory activity was evaluated against 
carrageenin  induced  paw  edema  in  albino  rats  of 
either sex weighing 150-250g each (20-21). Prior to 
experiments 0.05ml of freshly prepared suspension 
of carrageenin (1.0%) in 0.9% saline was injected. 
One group of six rats was kept as control and other 
groups were pre-treated with the test and standard 
drugs  at  doses  plethysmographically  of  100  mg/
kg  orally.  Rat  paw  volume  was  measured  before 
and 3 hrs after treatment with carrageenin. Increase 
in  volume  of  paw  in  each  group  was  measured 
and  percentage  of  anti-inflammatory  activity  was 
calculated by formula: 
Percentage anti-inflammatory activity =          
Where Vt and Vc are the volume of paw in edema in 
drug treated and control group respectively. The ED80 
values calculated from the data generated are shown in 
table 2, where ED80 is the concentration of the drug 
to produce 80 % response in the animal (21,22).
In vitro testing  [Colorimetric COX (ovine) Inhibitor 
Screening Assay Kit]
One hundred and sixty microliters of the assay buffer 
and 10 µl of heme were added to the background 
wells. Similarly 150 µl of the assay buffer, 10 µl 
of heme and 10 µl of enzyme (COX-2) was added 
to each of the 3 (100% Initial Activity Wells) wells 
as  well  as  to  3  (Inhibitory Activity Wells)  wells. 
Then 10 µl of inhibitor was added to the inhibitory 
activity wells while 10 µl of the solvent in which the 
inhibitors were dissolved was added to each of the 
100% initial activity and background wells. These 
plate were carefully shaken for a few seconds and 
incubated for 5 minutes at 25°C and then 20 µl of 
the colorimetric substrate solution was added to all 
wells. Then 20 µl of arachidonic acid was added to 
all wells and the plates were shaken carefully for a 
few seconds and incubated at 25°C for 5 min. The 
absorbance  was  measured  at  590  nm  using  plate 
reader. The absorbance and the calculated IC80 values 
are shown in table 3 where IC80 is the concentration 
of drug required to inhibit 80 % of the enzyme.
QSAR Analysis
Data Set
The builder module of the Vlife MDS was used to 
generate molecular models of a series of chalcone 
derivatives.  These  were  then  energy-minimized 
using the Merck Molecular Force Field (MMFF). 
The structures were energy-minimized until the root 
mean square (rms) gradient reached to the value of 
0.001 kcal mol-1 A°. The charge equilibration method 
was used to assign atomic partial charges to each of 
the compounds. pED80 values that is the negative 
in vivo and in vitro COX-2 inhibitory activity. QSAR 
analysis  was  performed  to  identify  the  structural 
features  responsible  for  the  targeted  activity. The 
outcome of this work is likely to characterize the 
structural  requirements  of  1,3-diaryl-2-propen-1-
ones  for  anti-inflammatory  activity,  mediated  by 
COX-2 inhibition differentially.
EXPERIMENTAL 
Twenty four 1,3-diarylprop-2-en-1-ones derivatives 
(Figure. 1) were synthesized by  Claisen-Schmidt 
condensation (18,19) and evaluated for their anti-
inflammatory  activity.  Among  them,  chalcones 
XIII-XVIII are new compounds. The purity of the 
compound was confirmed by TLC using, silica gel 
G as stationary phase and ethyl acetate: chloroform 
(1:2) as mobile phase. The IR spectra were recorded 
on Jasco FT/IR 4100 spectrophotometer.  1H NMR 
spectra were recorded on Varian NMR 400 MHz 
spectrometer using DMSO as a solvent and TMS as 
internal standard. The mass spectra of the compounds 
were obtained on Micro Mass Q-Top, YA-105. The 
substituent are shown in table 1. 
Procedure  for  synthesis  of  1,3-diarylprop-2-en-1-
ones (I-XXVI)18 
To a stirring solution of aldehyde (0.01 mol) in 
ethanol at room temperature was added 10 ml of 
10% sodium hydroxide. To this mixture was added 
0.01 mol of the corresponding ketone dropwise 
with constant stirring. The stirring was continued 
until final product was precipitated. The product 
was filtered, washed with water and recrystallized 
from ethanol to give the respective 1,3-diarylprop-
2-en-1-ones. The NMR data of synthesized 1,3-
disubstituted prop-2-enones are shown in table 1. 
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Fig. 1: Synthesis of 1,3-diarylprop-2-en-1-ones
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Figure 1. Synthesis of 1,3-diarylprop-2-en-1-ones. 
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Table 1. Ar and Ar` substituents and NMR data of the propenones I - XXIV. 
Comp. No. Ar Ar` NMR (DMSO) δ
I 4-methoxyphenyl 4-chlorophenyl
7.65-7.80 (m, 8H, aromatic) 7.50 (d, 1H, CH=CH, J=15.7 Hz), 7.53 (d, 1H, CH=CH, J=15.7 
Hz),  3.84 (s, 3H, OCH3) 
II 4-chlorophenyl 4-chlorophenyl 7.21-7.79 (m, 8H, aromatic) 7.49 (d, 1H, CH=CH, J=15.6 Hz), 7.22 (d, 1H, CH=CH, J=15.6 Hz) 
III 4-methyl phenyl 4-chlorophenyl
7.00-7.92 (m, 8H, aromatic) 7.61 (d, 1H, CH=CH, J=15.7 Hz), 7.09 (d, 1H, CH=CH, J=15.7 
Hz), 2.38 (s, 3H, CH3) 
IV 4-bromo phenyl 4-chlorophenyl 7.31-7.92 (m, 8H, aromatic) 7.48 (d, 1H, CH=CH, J=15.5 Hz), 7.30 (d, 1H, CH=CH, J=15.5 Hz) 
V 4-nitro phenyl 4-chlorophenyl 7.34-7.76 (m, 8H, aromatic) 7.62 (d, 1H, CH=CH, J=15.7 Hz), 7.29 (d, 1H, CH=CH, J=15.7 Hz)
VI
NN-dimethyl-4-
aminophenyl
4-chlorophenyl
7.49-8.10 (m, 8H, aromatic) 7.52 (d, 1H, CH=CH, J=15.8 Hz), 7.22 (d, 1H, CH=CH, J=15.8 
Hz), 2.24 (s, 6H, (N(CH3)2) 
VII 4-methoxyphenyl
3,4,5-trimethoxy 
phenyl
7.35-7.71 (m, 6H, aromatic) 7.42 (d, 1H, CH=CH, J=15.6 Hz), 7.14 (d, 1H, CH=CH, J=15.6 
Hz), 3.88 (s, 12H, OCH3) 
VIII 4-chlorophenyl
3,4,5-trimethoxy 
phenyl
7.18-7.79 (m, 6H, aromatic) 7.58 (d, 1H, CH=CH, J=15.7 Hz), 7.21 (d, 1H, CH=CH, J=15.7 
Hz). 3.84 (s, 9H, OCH3) 
IX 4-methyl phenyl
3,4,5-trimethoxy 
phenyl
7.00-7.92 (m, 6H, aromatic) 7.51 (d, 1H, CH=CH, J=15.5 Hz), 7.09 (d, 1H, CH=CH, J=15.5 
Hz), 3.84 (s, 9H, OCH3), 2.34 (s, 3H, CH3)
X 4-bromo phenyl
3,4,5-trimethoxy 
phenyl
7.11-7.52 (m, 6H, aromatic) 7.58 (d, 1H, CH=CH, J=15.7 Hz), 7.29 (d, 1H, CH=CH, J=15.7 
Hz) 3.88 (s, 9H, OCH3) 
XI 4-nitro phenyl
3,4,5-trimethoxy 
phenyl
7.14-7.46 (m, 6H, aromatic) 7.60 (d, 1H, CH=CH, J=15.8 Hz), 7.22 (d, 1H, CH=CH, J=15.8), 
3.72 (s, 9H, OCH3) 
XII
NN-dimethyl-4-
aminophenyl
3,4,5-trimethoxy 
phenyl
7.39-7.70 (m, 6H, aromatic) 7.68 (d, 1H, CH=CH), 7.26 (d, 1H, CH=CH), 3.80 (s, 9H, 
OCH3), 2.31 (s, 6H, (N(CH3)2)
XIII 4-methoxyphenyl Indol-3-yl
7.45-8.12 (m, 8H, aromatic) 7.38 (s, 1H, NH), 6.71 (s, 1H, 2-indole), 7.68 (d, 1H, CH=CH), 
7.22 (d, 1H, CH=CH), 3.84 (s, 3H, OCH3) and J(Vinylic H) = 15.6 Hz. 
XIV 4-chlorophenyl Indol-3-yl
7.51-7.79 (m, 8H, aromatic), 7.41 (s, 1H, NH), 6.71 (s, 1H, 2-indole), 7.62 (d, 1H, CH=CH, 
J=15.7 Hz), 7.27 (d, 1H, CH=CH, J=15.7 Hz) 
XV 4-methyl phenyl Indol-3-yl
7.40-7.92 (m, 8H, aromatic), 7.34 (s, 1H, NH), 6.61 (s, 1H, 2-indole), 7.57 (d, 1H, CH=CH, 
J=15.6 Hz), 7.29 (d, 1H, CH=CH, J=15.6 Hz), 2.29 (s, 3H, CH3) 
XVI 4-bromo phenyl Indol-3-yl
7.45-7.88 (m, 8H, aromatic), 7.39 (s, 1H, NH), 6.71 (s, 1H, 2-indole), 7.61 (d, 1H, CH=CH, 
J=15.8 Hz), 7.22 (d, 1H, CH=CH, J=15.8 Hz) 
XVII 4-nitro phenyl Indol-3-yl
7.51-7.91 (m, 8H, aromatic), 7.42 (s, 1H, NH), 6.77 (s, 1H, 2-indole), 7.54 (d, 1H, CH=CH, 
J=15.9 Hz), 7.14 (d, 1H, CH=CH, J=15.9) 
XVIII
N,N-dimethyl-4-
aminophenyl
Indol-3-yl
7.49-8.10 (m, 8H, aromatic) 7.34 (s, 1H, NH), 6.66 (s, 1H, 2-indole), 7.50 (d, 1H, CH=CH, 
J=15.5 Hz), 7.20 (d, 1H, CH=CH, J=15.5 Hz), 2.29 (s, 6H, (N(CH3)2) 
XIX 4-methoxyphenyl
N,N-dimethyl-4 
aminophenyl
7.45-7.70 (m, 8H, aromatic) 7.58 (d, 1H, CH=CH, J=15.5 Hz), 7.21 (d, 1H, CH=CH, J=15.5 
Hz), 3.82 (s, 3H, OCH3). 2.27 (s, 6H, (N(CH3)2)
XX 4-chlorophenyl
N,N-dimethyl-4 
aminophenyl
7.61-7.99 (m, 8H, aromatic) 7.62 (d, 1H, CH=CH, J=15.6 Hz), 7.28 (d, 1H, CH=CH, J=15.6 
Hz). 2.31 (s, 6H, (N(CH3)2) 
XXI 4-methyl phenyl
N,N-dimethyl-4 
aminophenyl
7.20-7.72 (m, 8H, aromatic) 7.46 (d, 1H, CH=CH, J=15.5 Hz), 7.19 (d, 1H, CH=CH, J=15.5 
Hz), 2.33 (s, 3H, CH3). 2.34 (s, 6H, (N(CH3)2)
XXII 4-bromo phenyl
N,N-dimethyl-4 
aminophenyl
7.42-7.89 (m, 8H, aromatic) 7.59 (d, 1H, CH=CH, J=15.7 Hz), 7.29 (d, 1H, CH=CH, J=15.7 
Hz). 2.24 (s, 6H, (N(CH3)2) 
XXIII 4-nitro phenyl
N,N-dimethyl-4 
aminophenyl
7.27-7.86 (m, 8H, aromatic) 7.54 (d, 1H, CH=CH, J=15.8 Hz), 7.22 (d, 1H, CH=CH, J=15.8 
Hz). 2.22 (s, 6H, (N(CH3)2)
XXIV
N,N-dimethyl-4 
aminophenyl
N,N-dimethyl-4 
aminophenyl
7.46-8.05 (m, 8H, aromatic) 7.57 (d, 1H, CH=CH, J=15.5 Hz), 7.30 (d, 1H, CH=CH, J=15.5 
Hz), 2.24 (s, 9H, 2(N(CH3)2) 233
logarithms to the base 10 of the IC80 values, for each 
compound were used for the present QSAR study. 
The physicochemical properties of each compound 
were  specified  using  various  descriptors,  which 
delineate  liphophillic,  conformational,  electronic, 
spatial,  structural,  thermodynamic  and  quantum 
mechanical  information.  The  selected  descriptors 
included the X-component of dipole moment (XD), 
valence molecular connectivity index (chiV3) and 
log of partition coefficient calculated as per a atomic 
contribution model (SLogP). Based on appropriate 
representation  of  quantitative  sub-classes  of 
biological  activity,  from  the  24  compounds  18 
were randomly chosen for the training set and the 
remaining  compounds  were  used  as  test  set  for 
checking  the  external  predictivity  of  generated 
QSAR models. The selected model developed by 
using the training set was used to predict the activity 
of the compounds in the test set and subsequently to 
predict the activity of all 24 compounds by leaving a 
group out every time. 
Full Search Multiple Linear Regression Method
A relationship between independent and dependent 
variables  (physicochemical  descriptors  and 
biological activities, respectively) were determined 
statistically  using  regression  analysis.  Linear 
regression was achieved by fitting a best-fit straight 
line  to  the  data  using  the  least  squares  method. 
Descriptors that are included in a reasonable QSAR 
equation should exhibit high correlation to biological 
activity and low inter-correlation so that a diverse 
set of independent variables with high correlation to 
activity are selected. High correlation with targeted 
activity followed by low inter-correlation between 
descriptors  were  the  criteria  which  were  used for 
selection of descriptors for equation and the quality of 
fit for a regression equation was assessed relative to 
its correlation coefficient and standard deviation. The F 
value represents the level of statistical significance 
of the regression. Quality of selected models was 
further  ascertained  to  select  the  best  model  from 
cross-validated squared correlation coefficient (q2). In 
Comp. No % Reduction in Edema 
(±SD)*
pED80
I 46.11 (±1.49) -0.04844
II 97.24 (±0.92) 0.2757
III 89.22 (±1.06) 0.2382
IV 94.60 (±0.74) 0.2636
V 78.44 (±0.67) 0.1823
VI 34.05 (±0.84) -0.1801
VII 60.20 (±2.16) 0.0673
VIII 88.44 (±0.97) 0.2344
IX 26.65 (±0.47) -0.2865
X 85.32 (±1.46) 0.2188
XI 33.06 (±0.84) -0.1928
XII 16.54 (±1.24) -0.4937
XIII 56.89 (±0.92) 0.0427
XIV 97.08 (±1.40) 0.2749
XV 75.94 (±1.12) 0.1682
XVI 93.09 (±0.53) 0.2566
XVII 83.24 (±0.45) 0.2081
XVIII 52.92 (±0.96) 0.0113
XIX 69.88 (±1.07) 0.1321
XX 62.15 (±0.81) 0.0811
XXI 42.18 (±0.58) -0.0870
XXII 60.58 (±1.30) 0.07007
XXIII 27.62 (±1.35) -0.2710
XXIV 12.82 (±1.04) -0.6043
Ibuprofen 88.09 (±0.86)
Table 2. Anti-inflammatory activity of synthesized compounds 
I - XXIV.
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Table  3.  Percentage  (%)  of  COX-2  inhibitory  activity  of  the 
synthesized compounds I - XXIV.
Compd. no. Conc.
µg/ml
Average Absorbance 
(600 nm)
Background Well - 0.248
100% Initial Activity Well - 0.420
I 10 0.272
II 10 0.367
III 10 0.359
IV 10 0.312
V 10 0.328
VI 10 0.258
VII 10 0.306
VIII 10 0.366
IX 10 0.266
X 10 0.351
XI 10 0.260
XII 10 0.297
XIII 10 0.317
XIV 10 0.398
XV 10 0.316
XVI 10 0.305
XVII 10 0.358
XVIII 10 0.330
XIX 10 0.335
XX 10 0.324
XXI 10 0.297
XXII 10 0.317
XXIII 10 0.275
XXIV 10 0.262234
the relation for q2 shown below,
q2 = 1 – PRESS/TOTAL
Σ(Ypredicted - Yobserved)2 is the predictive error sum of 
squares (PRESS). Σ(Yobserved - Ymean)2 is the total sum 
of  squares  (TOTAL),  where  Ypredicted,  Yobserved,  and 
Ymean are the predicted, observed, and mean values 
of activity, respectively. For a regression model, r2 
was used to describe the fitness of data and fitness 
is considered to improve as r2 approaches 1. Thus 
models  having  correlation  coefficient  above  0.7 
were used to check the external predictivity while 
the significance of the model was decided on the 
basis  of  F  value.  Models  showing  q2  below  0.6 
were discarded. The selected model fulfilling above 
criteria is given in table 4 and correlation matrix of the 
descriptors in the selected model is given is table 5. 
Activity prediction 
To assess a QSAR model systematically, a reliable 
validation is required. Usually, a QSAR model is 
evaluated  by  the  predictive  results  for  the  given 
data-set. Selected models having r2 above 0.7 were 
checked for their external predictivity. The observed 
and  the  predicted  values  for  anti-inflammatory 
activity are shown in table 6.
RESULTS  AND  DISCUSSION 
In  the  present  work  some  1,3-diarylpropenone 
derivatives  were  synthesized  by  nucleophilic 
condensation of aldehyde and ketones as per reported 
procedure. The purity and structure products were 
confirmed  by  chromatographic  and  spectral  data 
analysis.  The  IR  absorption  bands  in  the  range 
from 1540-1559 and 1655-1686 cm-1 indicated the 
presence  of  a  conjugated  carbonyl  group  (C=C-
C=O) and confirmed the formation of the propenone 
derivatives.  The  1H  NMR  spectrum  of  these 
compounds shows the presence of two doublets of 
vinylic protons at δ 7.09 to 7.68 (J = 15.5 to 15.9 
Hz) indicating presence of only the E-isomers of all 
compounds including the compounds with the Ar`, 
Indol-3-yl substituent.
The compounds were screened for anti-inflammatory 
activity  by  carrageenin  induced  rat  paw  edema 
method, using ibuprofen as standard. The COX-2 
inhibitory activity was also checked and a comparative 
account  of  both  activities  for  the  24  synthesized 
compounds is presented graphically in figure 2. The 
correlation coefficient for in vitro COX-2 inhibition 
versus the in vivo anti-inflammatory activity is 0.61. 
This value is an indication that COX-2 inhibition 
may  not  be  the  sole  mechanism  by  which  these 
compounds act as anti-inflammatory agents and other 
mechanisms like inhibition of the lipoxygenase and 
heme oxygenase-1 by the active compounds should 
also be studied.
Similarly,  amongst  the  compounds  showing  good 
anti-inflammatory  activity,  the  low  residuals  of 
Table 4. QSAR model generated for the in vivo anti-inflammatory activity.
QSAR model N r2 q2 F value Pred r2 SE
pED80 = 0.3952 SlogP - 0.0214 chiV3 - 0.053 XD - 1.0123 19 0.794 0.657 31.00 0.718 0.105
Comp. 
No.
Observed
pED80
Predicted 
pED80*
Residuals*
I -0.048 -0.076 0.028
II 0.275 0.251 0.025
III 0.238 0.223 0.015
IV 0.263 0.301 -0.037
V 0.182 0.112 0.070
VI -0.180 -0.020 -0.160
VII 0.067 -0.023 0.090
VIII 0.234 0.096 0.138
IX -0.286 -0.067 -0.219
X 0.218 0.153 0.066
XI -0.192 -0.079 -0.114
XII -0.493 -0.358 -0.135
XIII 0.042 0.095 -0.052
XIV 0.274 0.267 0.008
XV 0.168 0.088 0.080
XVI 0.256 0.349 -0.092
XVII 0.208 0.173 0.035
XVIII 0.011 -0.146 0.157
XIX 0.132 -0.160 0.292
XX 0.081 0.064 0.017
XXI -0.087 -0.249 0.162
XXII 0.070 0.100 -0.030
XXIII -0.271 -0.206 -0.065
XXIV -0.604 -0.460 -0.144
Table 6. Observed in  vivo anti-inflammatory activity, predicted 
activity and residuals. 
* Calculated by Vlife MDS 3.5 * All the values are calculated on the Vlife sciences MDS 3.5.
Slog P chiV3 XD
Slog P 1.000000 0.036276 0.214725
chiV3 0.036276 1.000000 0.090551
XD 0.214725 0.090551 1.000000
Table 5. Correlation matrix of descriptors used in the study. 
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compound  numbers  II,  III,  IV  and  XIV  indicate 
good predictability of the QSAR model for these 
compounds  while  in  the  case  of  the  remaining 
active compounds, V, VIII, X, XVI and XVII, the 
predicted activity deviates highly from the observed 
activity. These results also indicate that the selected 
set of descriptors have relevance to a certain target 
receptor  whereas  some  other  modes  of  action 
involving different receptors may have a significant 
contribution in the observed anti-inflammatory action 
of the compounds whose predicted activities show 
large deviations from their observed activities.
The  selected  QSAR  model  was  found  best  to 
express  anti-inflammatory  activity  as  confirmed 
by  validation  of  the  model  judging  internal  and 
external predictivity and other statistical terms like 
the predicted r2, F value and q2. The variable terms 
in the equation together yield a good correlation to 
the targeted activity showing low correlation among 
themselves and hence show a diverse set of variables 
influencing biological activity. As indicated in table 5 
the anti-inflammatory activity increases by increase 
in SlogP and decreases in chiV3 and XD within the 
limits explored for this work. 
As  it  is  evident  from  the  compounds  producing 
better activity, an electronegative atom like chlorine 
or  bromine  are  distant  from  the  electron  rich 
pyrrole  of  the  indolyl  substituent  and  structural 
features enhancing the dipole are likely to improve 
activity.  Similarly  the  increase  in  the  multiplicity 
of substituents could positively contribute to chiV3 
and  hence  compounds  with  multiple  substituents 
like  methoxy  and  dimethylamino  are  less  active. 
Atomic contributions to partition coefficient which 
would  increase  hydrophilicity  and  polarity  and 
hence  decrease  in  the  partition  coefficient  within 
the range covered by the compounds of this work 
could possibly improve anti-inflammatory activity. 
The  presence  of  a  4-bromophenyl  and  indolyl 
substituents in compound XIV resulted in good anti-
inflammatory activity but the COX-2 inhibition was 
relatively low. 
CONCLUSION 
QSAR analysis on a structurally diverse but small 
set of propenones has led to the identification of 
structural, electronic and steric factors contributing to 
anti-inflammatory activity and COX-2 selectivity. Robust 
statistical  parameters  handled  the  physicochemical 
descriptors effectively to rule out chance co-relations 
with  an  acceptable  level  of  approximations. 
Evaluation and comparison of the QSAR analysis 
with the results of COX-2 selectivity and potency led 
to understanding that though, COX-2 inhibition may 
possibly be the mechanism for the anti-inflammatory 
action but it does not solely account for the anti-
inflammatory activity shown by all the synthesized 
propenone  derivatives.  The  correlation  of  the 
exhibited activity is required to be explored with 
other targets for anti-inflammatory compounds like 
heme oxygenase-1, lipoxygenase, etc.  
Moreover,  the  awareness  and  understanding  of 
the  descriptors  influencing  both  the  affinity  and 
selectivity  properties  of  these  compounds  could 
provide an opportunity to understand and optimize 
appropriate features of the ligand structures which 
correlate with the biological data. As a consequence, 
the outcome of this study could be useful as a guide 
for further development of safer COX-2 inhibitors 
and anti-inflammatory drugs. 
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